Moving from one-size-fits-all treatment to personalized therapy - how NAMs enable medicine tailored to each individual patient
Same drug, same dose for everyone
Right drug for the right patient
Tissue sample collected from patient tumor or affected organ
Patient cells grown into mini-organ that matches their biology
Multiple drugs tested on the patient's organoid in parallel
Machine learning predicts optimal treatment and dose
Patient receives drug proven to work on their specific cells
Mini-organs grown directly from patient tissue that retain the genetic and cellular characteristics of the original tumor or organ. Can be stored and used for multiple drug tests.
Virtual models built from individual patient data including genomics, medical history, and biomarkers. Can simulate drug responses before real treatment.
Machine learning algorithms that analyze patient biomarkers, genetic variants, and historical data to predict drug efficacy and side effects.
Genetic tests that reveal how a patient will metabolize specific drugs, helping determine the right dose and avoiding adverse reactions.
Major cancer centers offer patient organoid drug testing as standard of care, reducing trial-and-error prescribing
Electronic health records integrate with digital twin platforms, enabling real-time drug interaction predictions
AI systems recommend personalized drug combinations based on comprehensive patient data and organoid responses
Every patient has access to their own biological avatar - organoids and digital twins that travel with their medical records
Learn more about how NAMs are enabling precision medicine
Organoid Technology Digital Twins NAMs Ecosystem